byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmoloogilised vahendid - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosupressandid - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloogilised vahendid - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukeemia, karvane rakk - antineoplastilised ained - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
gemcitabine accord 100mg/ml infusioonilahuse kontsentraat
accord healthcare b.v. - gemtsitabiin - infusioonilahuse kontsentraat - 100mg 1ml 10ml 1tk; 100mg 1ml 15ml 1tk; 100mg 1ml 20ml 1tk
aggrastat infusioonilahuse kontsentraat
correvio - tirofibaan - infusioonilahuse kontsentraat - 250mcg 1ml 50ml 1tk
trombopriv infusioonilahuse kontsentraat
uab via pharma - tirofibaan - infusioonilahuse kontsentraat - 250mcg 1ml 50ml 1tk
gemcitabine kabi 40 mg/ml infusioonilahuse kontsentraat
fresenius kabi oncology plc - gemtsitabiin - infusioonilahuse kontsentraat - 40mg 1ml 50ml 1tk; 40mg 1ml 25ml 1tk; 40mg 1ml 5ml 1tk
vasonit retard toimeainet prolongeeritult vabastav tablett
g.l. pharma gmbh - pentoksüfülliin - toimeainet prolongeeritult vabastav tablett - 600mg 50tk